The rising burden of diabetes is a big threat to sustainable development goals as health and development is closely linked, said Peter Ulvskjold, Corporate Vice President of Novo Nordisk.
“Development cannot be achieved without sound health,” Peter said at a press meet on “Novo Nordisk’s commitments towards sustainability” at Changing Diabetes in Children Clinic, BIRDEM 2 in Dhaka Monday.
The United Nations has recognised diabetes among other non-communicable disease as a major challenge for sustainable development. Currently, one adult in 11 people living with diabetes and it will stand one adult in 10 by 2040, Peter said.
In Bangladesh, 7.1 million people are living with diabetes and 129,313 people died in 2015 due to diabetes-related diseases, according to International Diabetes Federation. Every six seconds a person dies of diabetes.
Novo Nordisk is supporting many initiatives in partnership with Diabetic Association of Bangladesh (DAB) to reduce the burden of diabetes, said Professor AK Azad Khan, president of DAB.
“Changing diabetes® in children (CDiC), Changing Diabetes® Brand Ambassador and Distance Learning Programme (DLP) are to name few”, Anand Shetty, managing director of Novo Nordisk Bangladesh said.
Established in 2010, CDiC is the world’s largest clinic for children with Type 1 diabetes, to improve the access to diabetes care and help these children live better lives, said Md Sayef Uddin, Secretary General of DAB.
Insulin is life for children living with diabetes. Three clinics have been established in Dhaka, Faridpur and Chittagong, where 2,100 children have been enrolled. They are getting free insulins, glucometers, test strips, monthly consultation and other relevant supports under this project.
Novo Nordisk manufactures human insulin dial with SKF and Transcom Distribution distributes the product across the country.
“Novo Nordisk is giving top priority to support this growing treatment need of children living with diabetes. We believe that a healthy economy, environment and society are fundamental to long-term business success” said Dr. Mohammad Saiful, Head of Marketing of Novo Nordisk Bangladesh.
Novo Nordisk is producing Human Insulin vials with Eskayef Pharma and Transcom Distribution Company distribute across the country, according to a statement.